-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA GRANTS PRIORITY REVIEW TO GENENTECH’S GAZYVA FOR ADULTS WITH PRIMARY MEMBRANOUS NEPHROPATHY

Reuters·07/15/2026 05:00:00

Please log in to view news